Literature DB >> 33706248

A nationwide analysis of maternal morbidity and acute postpartum readmissions in women with epilepsy.

Barbara M Decker1, Dylan Thibault2, Kathryn A Davis3, Allison W Willis4.   

Abstract

OBJECTIVE: To compare maternal delivery hospitalization characteristics and postpartum outcomes in women with epilepsy (WWE) versus women without common neurological comorbidities.
METHODS: We performed a retrospective cohort analysis of index characterizations and short-term postpartum rehospitalizations after viable delivery within the 2015-2017 National Readmissions Database using International Classification of Diseases, Tenth Revision codes. Wald chi-squared testing compared baseline demographic, hospital and clinical characteristics and postpartum complications between WWE and controls. Multivariable logistic regression models examined odds of nonelective readmissions within 30 and 90 days for WWE compared to controls (alpha = 0.05).
RESULTS: A total of 38,518 WWE and 8,136,335 controls had a qualifying index admission for delivery. Baseline differences were most pronounced in Medicare/Medicaid insurance (WWE: 58.2%, controls: 43%, p < 0.0001), alcohol/substance abuse (WWE: 8.3%, controls: 2.5%, p < 0.0001), psychotic disorders (WWE: 1.2%, controls 0.1%, p < 0.0001), and mood disorder (WWE: 15.5%, controls: 3.7%, p < 0.0001). At the time of delivery, WWE were more likely to have edema, proteinuria, and hypertensive disorders (WWE: 19%, controls: 12.9%, p < 0.0001); a history of recurrent pregnancy loss (WWE: 1%, controls: 0.4%, p < 0.0001); preterm labor (WWE: 7.3%, controls: 4.8%, p < 0.0001), or presence of any Center for Disease Control severe maternal morbidity indicator (WWE: 3.2%, controls: 0.6%, p < 0.0001; AOR 5.16, 95% CI 4.70-5.67, p < 0.0001). A higher proportion of WWE were readmitted within 30 days (WWE: 2.4%, controls: 1.1%) and 90 days (WWE: 3.7%, controls: 1.6%). After adjusting for covariates, the odds of postpartum nonelective readmissions within 30 days (AOR 1.86, 95% CI 1.66-2.08, p-value <0.0001) and 90 days (AOR 2.04, 95% CI 1.83-2.28, p-value <0.0001) were higher in WWE versus controls.
INTERPRETATION: Women with epilepsy experienced critical obstetric complications and a higher risk of severe maternal morbidity indicators at the time of delivery. Although relatively low, nonelective short-term readmissions after delivery were higher in WWE than women without epilepsy or other common neurological comorbidities. Further research is needed to address multidisciplinary care inconsistencies, improve maternal outcomes, and provide evidence-based guidelines.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Maternal morbidity; National readmission database; Population-based; Postpartum; Women with epilepsy

Mesh:

Year:  2021        PMID: 33706248      PMCID: PMC8035274          DOI: 10.1016/j.yebeh.2021.107874

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  26 in total

1.  Development and validation of a case definition for epilepsy for use with administrative health data.

Authors:  Aylin Y Reid; Christine St Germaine-Smith; Mingfu Liu; Shahnaz Sadiq; Hude Quan; Samuel Wiebe; Peter Faris; Stafford Dean; Nathalie Jetté
Journal:  Epilepsy Res       Date:  2012-06-22       Impact factor: 3.045

2.  Rate and causes of severe maternal morbidity at readmission: California births in 2008-2012.

Authors:  Anna I Girsen; Lillian Sie; Suzan L Carmichael; Henry C Lee; Megan E Foeller; Maurice L Druzin; Ronald S Gibbs
Journal:  J Perinatol       Date:  2019-08-28       Impact factor: 2.521

3.  Severe maternal morbidity: screening and review.

Authors:  Sarah K Kilpatrick; Jeffrey L Ecker
Journal:  Am J Obstet Gynecol       Date:  2016-08-22       Impact factor: 8.661

4.  Trends in the incidence, rate and treatment of miscarriage-nationwide register-study in Finland, 1998-2016.

Authors:  R Linnakaari; N Helle; M Mentula; A Bloigu; M Gissler; O Heikinheimo; M Niinimäki
Journal:  Hum Reprod       Date:  2019-11-01       Impact factor: 6.918

5.  Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States.

Authors:  Sarah C MacDonald; Brian T Bateman; Thomas F McElrath; Sonia Hernández-Díaz
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

6.  Severe Maternal Morbidity During Delivery Hospitalizations.

Authors:  Crystal Gibson; Angela M Rohan; Kate H Gillespie
Journal:  WMJ       Date:  2017-12

Review 7.  Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.

Authors:  C L Harden; K J Meador; P B Pennell; W A Hauser; G S Gronseth; J A French; S Wiebe; D Thurman; B S Koppel; P W Kaplan; J N Robinson; J Hopp; T Y Ting; B Gidal; C A Hovinga; A N Wilner; B Vazquez; L Holmes; A Krumholz; R Finnell; D Hirtz; C Le Guen
Journal:  Neurology       Date:  2009-04-27       Impact factor: 9.910

8.  Pregnancy-related complications and risk of postpartum readmission for seizures and epilepsy: A national study.

Authors:  Gabriela B Tantillo; Nathalie Jetté; Ji Yeoun Yoo; Joanne Stone; Marc Egerman; Mandip S Dhamoon
Journal:  Epilepsia       Date:  2020-08-12       Impact factor: 5.864

9.  Pregnancy rates and outcomes in women with and without MS in the United States.

Authors:  Maria K Houtchens; Natalie C Edwards; Gary Schneider; Kevin Stern; Amy L Phillips
Journal:  Neurology       Date:  2018-09-28       Impact factor: 9.910

10.  Maternal death in women with epilepsy: Smaller scope studies.

Authors:  Jakob Christensen; Claus Vestergaard; Bodil Hammer Bech
Journal:  Neurology       Date:  2018-09-26       Impact factor: 9.910

View more
  1 in total

1.  Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.

Authors:  Barbara M Decker; Dylan Thibault; Kathryn A Davis; Allison W Willis
Journal:  Neurology       Date:  2022-02-15       Impact factor: 11.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.